Rockefeller Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Rockefeller Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-344	Closed	-$11.5K	–	4862
2026 Q1	$11.5K	Buy	344 +333	+3,027%	+$13.1K	﹤0.01%	3937
2025 Q4	$509	Sell	11 -192	-95%	-$10.5K	﹤0.01%	4530
2025 Q3	$13.7K	Buy	+203	New	+$15.1K	﹤0.01%	3530

Rockefeller Capital Management's SLNO Position: Q2 2026 in Review

Rockefeller Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 344 shares — an estimated $11.5K sold.

Rockefeller Capital Management first reported a position in SLNO in Q3 2025 and held it in 3 quarters. The position peaked at $13.7K in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Rockefeller Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Rockefeller Capital Management sold 344 Soleno Therapeutics shares in Q2 2026, an estimated $11.5K.
Rockefeller Capital Management first reported a position in Soleno Therapeutics in Q3 2025 and held it in 3 quarters.
Rockefeller Capital Management's Soleno Therapeutics position peaked at $13.7K in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.